Cat. No. | Product name | CAS No. |
DCC2593 |
Hras-1y I-motif Probe-1
Novel Probe of the hras-1Y i-motif , selectively and directly interacting with the hras-1Y i-motif. |
|
DCC2594 |
Hrv-14 Inhibitor 3v
Inhibitor of human rhinoviruses serotype 14 (HRV-14) |
|
DCC2595 |
Hs-438
Novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia |
1430720-10-7 |
DCC2596 |
Hs-731
μ-Opioid Receptor Agonist |
547767-45-3 |
DCC2597 |
Hsa-5b
Novel anticancer Gold(III) agent with remarkable cytotoxicity to gastric cancer cells |
|
DCC2598 |
Hsd1237
Novel potent inhibitor of the recombinant FLT3 kinase and its mutant forms, blocking the proliferation of AML cell lines, harboring oncogenic FLT3-ITD mutations with remarkable IC50 values, which were comparable to the approved FLT3 inhibitor quizartinib, |
|
DCC2599 |
Hsgn-94
Novel inhibitor of lipoteichoic acid (LTA) biosynthesis, potently inhibiting S. aureus and E. faecalis growth and biofilm formation |
|
DCC2600 |
Hsk21542
Novel Peripherally-Restricted Kappa Opioid Receptor (KOR) Agonist with Antinociceptive and Antipruritic Effects |
|
DCC2601 |
Hsp27-in-i
Novel inhibitor of heat shock 27 kDa protein (HSP27), significantly inducing AR degradation in GBM cells via the proteasomal pathway, selectively inhibiting AR-overexpressed GBM cell growth with IC 50 values around 5 nM |
|
DCC2602 |
Hsp90-aha1 Inhibitor A16
Novel Hsp90-Aha1 chaperone complex formation inhibitor, enhancing F508del-CFTR channel activity |
4536-70-3 |
DCC2603 |
Hsp90-in-30f
Novel potent inhibitor of heat shock protein 90 (Hsp90), effectively reducing the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf |
|
DCC2604 |
Hsp90-in-89
Novel heat shock protein 90 (Hsp90) inhibitor |
1087140-75-7 |
DCC2605 |
Hsp90-in-s89
Novel heat shock protein 90 (Hsp90), more potent enantiomer |
313379-34-8 |
DCC2606 |
Htl0028016
Novel macrocyclic calcitonin gene-related peptide (CGRP) receptor antagonist |
|
DCC2607 |
Htl0028125
Novel macrocyclic calcitonin gene-related peptide (CGRP) receptor antagonist |
|
DCC2608 |
Htl26119
Novel allosteric antagonist of the glucagon-like peptide-1 receptor (GLP-1R) |
|
DCC2609 |
Htl6641
Novel, potent, selective, and orally efficacious dual antagonist of the orexin receptors |
|
DCC2610 |
hts05737
Novel activator of PC2 |
697229-30-4 |
DCC2611 |
Huhs029
Novel analgesic agent, activating TRPA1 and subsequently desensitizing the channel, exhibiting higher inhibitory activity than resveratrol |
|
DCC2612 |
Human Vitronectin (351-359)
Adhesive peptide (sequence 351-359 mapped on the Human Vitronectin Protein), covalent and selective functionalizing on glass and titanium surfaces, increasng osteoblast attachment and adhesion strength and to promoting osseointegration |
|
DCC2613 |
Hur-ligand-4
Novel human antigen R (HuR) ligand, acting as a HuR-RNA interferer |
|
DCC2614 |
Hy1-pt
Novel CK2-Specific Pt(II) Compound, Reversing Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments |
|
DCC2615 |
Hycanthone Mesylate
Inhibitor of apurinic endonuclease-1 (APE1) by direct protein binding |
23255-93-8 |
DCC2616 |
Hydro-1080
Activable Probe for Noninvasive Hydroxyl Radical Imaging, emitted in 1000-1400 nm after responding to ·OH |
|
DCC2617 |
Hydrocaffeoyl-fasudil 1d
Novel multitarget Fasudil derivative, inducing the NRF2 signature, promoting the expression of the antioxidant response enzymes HO-1 and NQO1, via a KEAP1-dependent mechanism |
|
DCC2618 |
Hydrolapachol
Novel potent and selective inhibitor of Schistosoma mansoni dihydroorotate dehydrogenase (SmDHODH) |
3343-38-2 |
DCC2619 |
Hydroxyellipticine-1a
Novel selective r(CGG)exp probe, improving pre-mRNA splicing defects, inhibiting formation of nuclear inclusions and RANT in a FXTAS cellular model |
109628-38-8 |
DCC2620 |
Hydroxymatairesinol
Natural antioxidant and anti-cancer agent, blocking the MAPK/NF-κB and activating Nrf2/HO-1 |
20268-71-7 |
DCC2621 |
Hydroxytriolein
Novel anticancer agent, inhibiting lung cancer cell proliferation via a PKCa and ERK1/2 dependent mechanism |
|
DCC2622 |
Hymenidin
Natural antagonist of serotonergic receptors and inhibitor of CDK5/p25 and GSK-3ß |
107019-95-4 |
DCC2623 |
Hys-32
Novel analogue of combretastatin A-4, enhancing connexin43 expression |
1528729-98-7 |
DCC2624 |
Hz-ma Hybrid 11b
Novel potent and selective inhibitor of fat mass obesity-associated protein (FTO), being selectively over alkylation repair homologue 5 (ALKBH5), another DNA/RNA demethylase |
|
DCC2625 |
Iag-10
Novel potent and selective inhibitor of human DNA polymerase kappa (hpol κ) |
|
DCC2626 |
Ianthellamide A
Selective kynurenine-3-hydroxylase inhibitor |
1374875-85-0 |
DCC2627 |
Ianthelliformisamine A Tfa Salt
Antibiotic enhancer against resistant Gram-negative bacteria |
1643593-28-5 |
DCC2628 |
Ianthelliformisamine B Tfa Salt
Antibiotic enhancer against resistant Gram-negative bacteria |
1643593-29-6 |
DCC2629 |
Ianthelliformisamine C Tfa Salt
Antibiotic enhancer against resistant Gram-negative bacteria |
1643593-30-9 |
DCC2630 |
Iap-in-1
Novel antagonist of IAP (inhibitor of apoptosis protein) |
1005342-47-1 |
DCC2631 |
Iaxo-101
Novel inhibitor of the cluster of differentiation 14 innate immunity pathway |
1202388-64-4 |
DCC2632 |
Ibe-667
Novel activator of LFA-1-ICAM-1 binding |
|
DCC2633 |
Ibl-302
First-in-class triple-acting PIM/PI3K/mTOR inhibitor, demonstrating single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines |
|
DCC2634 |
Ibpr001 Hydrochloride
Novel Aurora kinase inhibitor |
1192754-04-3 |
DCC2635 |
Ibpr002
Novel Aurora kinase inhibitor, revealing mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
1192754-38-3 |
DCC2636 |
Ibrutinib-bfl
Novel fluorescent irreversible inhibitor of Bruton's tyrosine kinase (BTK) |
|
DCC2637 |
Ibs399024
Novel HDAC6-selective inhibitor |
|
DCC2638 |
Ic2418
MmpL3 inhibitor, being active against drug-resistant Mycobacterium tuberculosis |
1432641-65-0 |
DCC2639 |
ica-27243
Neuronal Kv7 potassium channel activator |
325457-89-3 |
DCC2640 |
Icagen-4
Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5 |
|
DCC2641 |
Ical-36
Novel inhibitor of CALP, exhibiting affinity of 22.6 ± 8.0 μM for CALP and no interaction with the NHERF PDZ domains |
|
DCC2642 |
icec0943
Novel selective inhibitor of CDK7 |
|
DCC2643 |
Ici-185282
Potent thromboxane receptor antagonist |
106393-80-0 |
DCC2644 |
Ici-56780
Antimalarial agent, displaying blood schizonticidal activity against P.berghei |
28130-28-1 |
DCC2645 |
Iclaprim
Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms |
192314-93-5 |
DCC2646 |
Icl-ccic-0019
Novel potent and selective inhibitor of choline kinase alpha (CHKA) |
936498-64-5 |
DCC2647 |
Icl-sirt078
Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line |
1060430-64-9 |
DCC2648 |
Icpd62
Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines |
|
DCC2649 |
Icrf-193
DNA topoisomerase II inhibitor |
21416-88-6 |
DCC2650 |
Ict2700
Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers |
|
DCC2651 |
Id110460001
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1110883-26-5 |
DCC2652 |
Id110460002
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1172882-21-1 |
DCC2653 |
Id110460003
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1428367-46-7 |
DCC2654 |
idaverine
M1 and M2 Antagonist |
100927-13-7 |
DCC2655 |
Ide-in-37 Tfa Salt
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2656 |
Ide-in-63 Tfa Salt
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2657 |
Idh2 Inhibitor
Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer |
|
DCC2658 |
Idi-3783
Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor |
901031-43-4 |
DCC2659 |
Ido1/2 Inhibitor 4t
The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM) |
|
DCC2660 |
idoxifene
Selective ER modulator (SERM) |
116057-75-1 |
DCC2661 |
Idr-0081053
Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations |
|
DCC2662 |
Idr-0099118
Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions |
693804-72-7 |
DCC2663 |
Idr-1002
Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin |
|
DCC2664 |
Idr-1018 Tfa Salt
Novel immunomodulatory and antibiofilm innate defense regulator peptide |
|
DCC2665 |
Idrapril
Angiotensin converting enzyme (ACE) inhibitor |
127420-24-0 |
DCC2666 |
Iferanserin
Selective serotonin 5-HT2A receptor antagonist |
58754-46-4 |
DCC2667 |
Ifn-1 Inducer C3
Novel Type I Interferon Inducer |
442567-76-2 |
DCC2668 |
Ifn-1 Inducer E51
Novel Type I Interferon Inducer |
|
DCC2669 |
Ifn-1 Inducer L56
Novel Type I Interferon Inducer; Intercalator of DNA; Inhibitor of the retrovirus replications including HIV |
133671-68-8 |
DCC2670 |
Igf2bp2/imp2 Inhibitor 4
First Small-Molecule Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
DCC2671 |
Igf2bp2/imp2 Inhibitor 6
Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
DCC2672 |
Igf2bp2/imp2 Inhibitor 9
Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
DCC2673 |
Iglu-antagonist-21a
Highly potent fluorescent iGlu receptor antagonist |
|
DCC2674 |
Ihr-saha
Novel dual SMO-HDAC antagonist, retaining similar specificity for SAHA-targeted HDACs, disabling deviant Hedgehog signaling and preventing GLI binding to DNA |
|
DCC2675 |
Ikarugamycin
Natural Inhibitor of Clathrin-Mediated Endocytosis |
36531-78-9 |
DCC2676 |
Ikkß-in-124
Novel allosteric inhibitor of IκBα phosphorylation and NF-κB transcriptional activity through selective capture of the inactive conformation and hence blockade of IKKβ S177/S181 phosphorylation |
825608-40-0 |
DCC2677 |
Ilmofosine
Antineoplastic phospholipid, being effective against many tumor types, including ovary, non-small cell lung, kidney, and melanoma, exhibiting competitive inhibition of protein kinase C (PKC) activity |
83519-04-4 |
DCC2678 |
Iloperidone Hydrochloride
Dual D 2 /5-HT 2 antagonist as an antipsychotic agent |
1299470-39-5 |
DCC2679 |
Imarikiren Dihydrochloride
Novel orally effective direct renin inhibitor for treating diabetic nephropathy and hypertension |
1202265-90-4 |
DCC2680 |
Imb-xma0038
Novel anti-tuberculosis agent, targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase |
921812-26-2 |
DCC2681 |
Imb-yh-8
Novel inhibitor of protein kinase B (PknB), inhibiting PknB auto-phosphorylation and the phosphorylation of GarA by PknB in a dose-dependent manner |
17615-10-0 |
DCC2682 |
Imc-48
BCL2 i-motif-interactive compound, stabilizing or facilitating the folding of the i-motif |
106068-99-9 |
DCC2683 |
Imc-76
BCL2 i-motif-interactive compound, destabilizing or unfolding the i-motif |
98129-27-2 |
DCC2684 |
Imidacloprid
Insect neurotoxin, blocking nicotinic acetylcholine receptors and preventing acetylcholine from transmitting impulses between nerves |
105827-78-9 |
DCC2685 |
Imm-h004
Novel potent inhibitor of BV2 microglia activation, protecting PC12 cells and primary neurons against indirect toxicity mediated by exposure to conditioned medium (CM) from LPS-treated BV2 cells |
1456807-80-9 |
DCC2686 |
Imp-1002
Novel resistance breaking antimalarial N-myristoyltransferase (NMT) inhibitor, binding to NMT peptide binding pocket |
|
DCC2687 |
Imp-1700
Novel cell-active and potent inhibitor of bacterial DNA repair, potentiating quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus |
1458674-25-3 |
DCC2688 |
Imp2070
Novel Probe for NLRP3 Inflammasome Inhibitor MCC950 |
|
DCC2689 |
Impdh-in-1
First in-class allosteric inhibitor of a bacterial IMPDH, showing to counteract the activation by the natural positive effector, MgATP, and to block the enzyme in its apo conformation |
|
DCC2690 |
Imprimatin-c1
Novel plant immune-priming agent, acting as a partial agonist of salicylic acid |
|
DCC2691 |
Imprimatin-c2
Novel plant immune-priming agent, acting as a partial agonist of salicylic acid |
|
DCC2692 |
Imt007
Mtb growth inhibitor, inhibiting Mtb GlgB activity by interacting to its active site residues |
|
DCC2693 |
In-1130
Potent inhibitor of the TGF-β type I receptor activin receptor-like kinase 5 (ALK5) |
868612-83-3 |
DCC2694 |
In-1166
Novel ALK5 inhibitor |
945244-71-3 |
DCC2695 |
Incb018424 Racemic
Janus-associated kinase (JAK) inhibitor |
1160597-27-2 |
DCC2696 |
Incb059872 Tosylate
Novel potent and selective lysine-specific demethylase 1 (LSD1) inhibitor |
2081940-67-0 |
DCC2697 |
Ind-07
Novel selective Mtb-DHFR inhibitor as an antimycobacterial agent |
|
DCC2698 |
Ind31119
Novel selective inhibitor of PfHsp90, bypassing its highly similar human orthologs |
|
DCC2699 |
Ind45193
Antiprion agent, reducing PrP(Sc) levels in dividing and stationary-phase cells |
10024-04-1 |
DCC2700 |
Indazole-cl
Selective estrogen receptor modifier (SERM), being a selective ERß agonist |
848142-62-1 |
DCC2701 |
Indeloxazine Hydrochloride
Antidepressant and cerebral activator, acting as a serotonin releasing agent, norepinephrine reuptake inhibitor, and NMDA receptor antagonist, enhancing acetylcholine release via activation of the 5-HT4 receptor |
65043-22-3 |
DCC2702 |
Indimitecan Hydrochloride
Topoisomerase I (Top1) inhibitor |
915303-04-7 |
DCC2703 |
Indobufen
Platelet aggregation inhibitor acting as a reversible Cyclooxygenase>cyclooxygenase inhibitor |
63610-08-2 |
DCC2704 |
Indole-3-lactic Acid
Metabolite of tryptophan, reducing the interleukin-8 (IL-8) response after IL-1β stimulus, interacting with the transcription factor aryl hydrocarbon receptor (AHR) and preventing transcription of the inflammatory cytokine IL-8, being anti-inflammatory in |
1821-52-9 |
DCC2705 |
Indolmycin
Natural antibiotic, selectively inhibiting bacterial tryptophanyl-tRNA synthetase (TrpRS) |
21200-24-8 |
DCC2706 |
Indoluidin D
Novel inhibitor of dihydroorotate dehydrogenase (DHODH), promoting myeloid differentiation and inhibiting the proliferation of acute promyelocytic leukemia HL-60 cells, also suppressing cell growth in various other types of cancer cells |
|
DCC2707 |
Indotecan Hydrochloride
Topoisomerase I (Top1) inhibitor |
1228035-68-4 |
DCC2708 |
Indoxam
Novel sPLA2 inhibitor, suppressing murine endotoxic shock and LDL modification, blocking binding to the M-type receptor |
|
DCC2709 |
Indoxyl Sulfate
Metabolite of tryptophan, showing adverse effects on bones and the central nervous system, having been most frequently implicated as a contributor to renal disease progression and vascular disease |
487-94-5 |
DCC2710 |
Infraluciferin
NIR emitting firefly luciferin analogue |
|
DCC2711 |
Ingavirin
Novel inhibitor of the influenza virus reproduction, inhubiting the formation of the virus specific hemagglutinin |
219694-63-0 |
DCC2712 |
inh-32
Novel inhibitor of Ark1, the fission yeast member of the conserved Aurora kinase family |
915718-93-3 |
DCC2713 |
Inhib1x
Novel dual inhibitor of MAPKAPK5 and MAPKAPK2 |
1105659-16-2 |
DCC2714 |
Inhibitor R1
Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
DCC2715 |
Inhibitor R3
Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
DCC2716 |
Inos-in-10
Novel selective inhibitor of the iNOS, without affecting the eNOS isoform |
|
DCC2717 |
Inos-in-18
Novel Potent and Selective Inducible Nitric Oxide Synthase (iNOS) Inhibitor (IC50 = 74 nM) with high BBB permeability (Pe = 19.1 × 10-6 cm/s) for Parkinson's Disease |
|
DCC2718 |
Inos-in-d27
Novel Potent and Orally Active Inducible Nitric Oxide Synthase (iNOS) Dimerization Inhibitor with Efficacy in Rheumatoid Arthritis Mouse Model |
|
DCC2719 |
Inp1750
Novel putative inhibitor of type III secretion (T3S) in the Gram-negative pathogen Yersinia pseudotuberculosis and Chlamydia trachomatis |
76289-27-5 |
DCC2720 |
Ins015_037
Novel potent inhibitor of DDR1 tyrosine kinase |
|
DCC2721 |
Ins3-54-a26
Novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
328998-77-2 |
DCC2722 |
Ins48823
Activator of the P2Y6 receptor in bone, increasing survival of osteoclasts |
|
DCC2723 |
Int2-31
Blocker of the interaction of FAK and IGF-1R; Antagonist of the phosphorylation of tumor AKT |
16684-22-3 |
DCC2724 |
Intervenolin
Natural potent inhibitor of H. pylori DHODH, having greater efficacy for treatment of H. pylori infection |
|
DCC2725 |
Intoplicine
Inhibitor of both topoisomerase I and II via intercalating DNA helix |
125974-72-3 |
DCC2726 |
Inuloxin A
Natural Activator of Programmed Cell Death, leading to membrane damage, mitochondria alteration, chromatin condensation, and ROS accumulation |
|
DCC2727 |
Inz-4 [1585213-98-4]
Novel Potent Fungal-Selective Inhibitor of Mitochondrial Cytochrome bc1 |
1585213-98-4 |
DCC2728 |
Iodiconazole
Novel antifungal agent, exhibiting broad spectrum and potent activity against 12 kinds of clinically pathogenic fungi |
887138-63-8 |
DCC2729 |
Iodoclorgyline
Selective monoamine oxidase A inhibitor |
140163-68-4 |
DCC2730 |
Ipcs-1
Novel inhibitor of the plant inositol phosphorylceramide synthase ((IPCS), demonstrating herbicidal activity |
|
DCC2731 |
Iperoxo-bqca C6
Muscarinic Acetylcholine Receptor Hybrid Ligand, possessing noticeable M2/M4 mAChR selectivity |
|
DCC2732 |
Ipi-269609
Orally bioavailable inhibitor of Hedgehog signaling, inhibiting tumor initiation and metastasis in pancreatic cancer |
878204-96-7 |
DCC2733 |
Ipomeamarone
Natural toxic furanoterpenoid found in mold-damaged sweet potatoes |
20007-82-3 |
DCC2734 |
Ipomoeassin F
Natural inhibitor of the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor, binding Sec61α to Inhibit Protein Translocation |
|
DCC2735 |
Ipr-2025
Novel inhibitor of glioblastoma multiforme (GBM), inhibiting cell viability of low-passage patient-derived GBM spheroids, blocking tube-formation of endothelial cells in Matrigel, showing no effect on primary hematopoietic CD34+ progenitor spheroids or as |
1008664-84-3 |
DCC2736 |
ipr-456
Inhibitor of the uPAR·uPA protein-protein interaction, blocking cancer cell invasion |
892243-59-3 |
DCC2737 |
Iproclozide
Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI) |
3544-35-2 |
DCC2738 |
Ips-02001
Novel inhibitor of protein-protein interaction (PPI), targeting integrin αvβ3-osteopontin interface, blocking OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs, impairing downstream signaling of integrin |
|
DCC2739 |
Ipsalazide
Sulfasalazine analog, releasing 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract |
80573-03-1 |
DCC2740 |
Iqs-01.01rs
Novel potent inverse agonist of the chemokine receptor CXCR4, preventing CXCL12-mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines and primary cultures, with superior mobilizing properties in vivo |
|
DCC2741 |
Ir-1061
NIR-II cyanine dye for cancer treatment and diagnosis |
155614-01-0 |
DCC2742 |
Irak Inhibitor 3
Novel interleukin-1 (IL-I) receptor-associated kinase (IRAK) modulator |
1012343-93-9 |
DCC2743 |
Irak3 Degrader 23
Novel potent and selective degrader of IRAK3, inducing proteasome-dependent degradation of IRAK3 and showing both CRBN and IRAK3 binding for activity |
|
DCC2744 |
Irak4-in-13
Novel Orally Efficacious IRAK4 Inhibitor, Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma |
2454244-02-9 |
DCC2745 |
Irc-083864
Novel inhibitor of CDC25 phosphatases, actively against human cancer cells |
1142057-18-8 |
DCC2746 |
ire1-in-vii
Inhibitor of IRE1 endoribonuclease activity, strongly inhibiting XBP-1 splicing in an in vivo model of acute endoplasmic reticulum stress. |
20035-41-0 |
DCC2747 |
Irl-1620
ET B receptor agonist, showing anti-apoptotic activity and protecting neural cells in rats with cerebral ischemia |
142569-99-1 |
DCC2748 |
Isam-c032
Novel potent hA2BAR antagonist (Ki = 3.66 nM) |
|
DCC2749 |
Isatin-o
Neutral BBB crossing reactivator for acetylcholinesterase inhibited by paraoxon, also acting as anticonvulsant |
607-28-3 |
DCC2750 |
Isbogrel
Selective thromboxane A2 (TXA2) synthase inhibitor |
89667-40-3 |
DCC2751 |
Isir-005
Natural Stabilizer of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface |
|
DCC2752 |
Iso-dehydrozingerone
Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice |
22214-39-7 |
DCC2753 |
Isofagomine
Iminosugar, binding selectively to N370S glucocerebrosidase and restoring its correct conformation and, consequently, enhancing its activity |
169105-89-9 |
DCC2754 |
Isomazole
Potent inotropic agent, inhibiting both PDE3 and PDE4 |
86315-52-8 |
DCC2755 |
Isomyristicin
Natural essential oil, showing activity against T. muris |
18312-21-5 |
DCC2756 |
Isopedopeptin B
Natural antibacterial agent with cytotoxicity and hemolytic properties against a larger panel of Gram-negative bacteria |
|
DCC2757 |
Iso-ppads
P2X-purinoceptor antagonist |
207572-67-6 |
DCC2758 |
Isowighteone
Natural genistein derivetive with antibacterial and antifungal activities |
68436-47-5 |
DCC2759 |
Isoxaben
Inhibitor of the cellulose biosynthesis, inhibiting anisotropic cell expansion resulting in a severely swollen and stunted growth phenotype |
82558-50-7 |
DCC2760 |
Isox-inact
Biological Active Reagents |
|
DCC2761 |
Isph Inhibitor 23.20-tpp
Novel prodrug of potent IspH inhibitor, killing clinical isolates of several multidrug-resistant bacteria, including those from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia, Mycobacterium and Baci |
|
DCC2762 |
Isp-vt
Novel inhibitor of COX and neutrophil migration |
175796-45-9 |
DCC2763 |
Isq-1 Hydrochloride
Distinct IKur blocker |
405165-77-7 |
DCC2764 |
Ist-622
Unique topoisomerase inhibitor, showing significant growth-inhibitory effects against large-cell lung cancer (Lu-116) and gastric adenocarcinoma (St-4) |
128201-92-3 |
DCC2765 |
Isvy130
Novel Potent and Selective A3 Antagonist |
|
DCC2766 |
Ite-atra
Novel degrader of CRABP proteins |
|
DCC2767 |
Ite-conhch3
Novel highly potent (EC 50 = 1.6 nM) aryl hydrocarbon receptor (AhR) agonist with high affinity (K i = 88 nM) |
|
DCC2768 |
Itf3756
Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor, showing a remarkably low toxicity both in vitro and in vivo and increasing the function of regulatory T cells (Tregs) at well-tolerated concentrations |
2247608-27-9 |
DCC2769 |
Itf3985
Novel selective HDAC6 inhibitor |
|
DCC2770 |
ith12246
Novel PP2A ligand, protecting against memory impairment and focal cerebral ischemia in mice |
1228658-28-3 |
DCC2771 |
Ith12505
Novel neuroprotective agent |
488829-66-9 |
DCC2772 |
Ith15004
Novel, potent, selective, and BBB-permeable P2X7 antagonist |
|
DCC2773 |
Itx-4520
Novel highly potent, orally bioavailable hepatitis C virus (HCV) entry inhibitor |
1392116-37-8 |
DCC2774 |
Ityr-dbrmd
First-in-class iodothyronine deiodinase type 3 (DIO3) inhibitor, demonstratig attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI) |
|
DCC2775 |
Ivabradine
Selective inhibitor of the funny channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium |
155974-00-8 |
DCC2776 |
Ivde77
The first Ang IV-analogue being able to abolish IRAP-availability completely at the cell surface in vitro |
|
DCC2777 |
Ivq Hydrochloride
Prodrug of QVO, being quickly converted to QVO in mice and rats following administration, ameliorating hyperglycemia, and suppressing hepatic gluconeogenesis and activating AMPK signaling pathway in the liver tissues |
1803533-07-4 |
DCC2778 |
Iwp-051
Novel, orally available soluble guanylate cyclase (sGC) stimulator with once-daily dosing potential for the treatment of cardiovascular diseases |
1354041-91-0 |
DCC2779 |
Iwp2g9
Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation |
|
DCC2780 |
Iwr107
Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation |
|
DCC2781 |
Iy-iy-das
Novel potent noncleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells |
|
DCC2782 |
Iy-iy-ss-das
Novel potent and cleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells |
|
DCC2783 |
J-2156 Tfa Salt
Potent and selective agonist of human somatostatin receptor 4 (sst4), reducing mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model |
848647-56-3 |
DCC2784 |
Jak1-in-38a
Novel highly potent JAK1-selective inhibitor, exhibiting excellent selectivity over JAK2, JAK3, and TYK2 (IC 50 : JAK1 0.145 nM; JAK2 2.94 nM; JAK3 2.31 nM; TYK2 8.17 nM) |
|
DCC2785 |
Jak1-in-b61
Novel JAK1 inhibitor |
1360172-78-6 |
DCC2786 |
Jak2-in-7j
Novel selective Jak2 inhibitor, demonstrating a time-dependent knock-down of pSTAT5, a downstream target of Jak2 |
1224942-06-6 |
DCC2787 |
Jak3-in Tricyclic-1
Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
DCC2788 |
Jak3-in Tricyclic-2
Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
DCC2789 |
Jak3-in Tricyclic-3
Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
DCC2790 |
Jak3-in-4
Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
DCC2791 |
Jak3-in-5
Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
DCC2792 |
Jak-in-1
Novel potent JAK1/2/3 inhibitor |
1334673-53-8 |